2015
- From our perspective: The importance of the physical characteristics of generic drugs
- From our perspective: Atrial fibrillation, oral anticoagulant drugs, and their reversal agents
- From our perspective: The U.S. drug supply chain and patient safety
- From our perspective: Evaluating the changing landscape of health care antiseptics
- From our perspective: Patients deserve quality medications
2014
- From our perspective: Statisticians at CDER Part 1, roles and responsibilities
- From our perspective: Statisticians at CDER Part 2, activities outside of applications
- From our perspective: Clinical biomarker qualification
- From our perspective: Assessing, safeguarding pharmaceutical quality
- Generic Drug User Fee Amendments (GDUFA) of 2012 regulatory science program
- Atrial fibrillation and new oral anticoagulant drugs
- FDA actions reduce drug shortages but critical issues remain
- Drug development tools and the EXACT PRO initiative, part 1
- Drug development tools and the EXACT PRO initiative, part 2
- Drug development guidelines for Hepatitis C virus
- Drug safety -- past, present and the future
No hay comentarios:
Publicar un comentario